ITOS Profile
ITeos Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for cancer treatment. The company's proprietary immuno-oncology platform is designed to stimulate the immune system to attack cancer cells. ITeos' lead product candidate, EOS-448, is a monoclonal antibody that targets the T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), a checkpoint protein that can suppress T cell activation and effector function. ITOS-448 is currently in phase 1/2a clinical trials for the treatment of solid tumors.
ITeos has a pipeline of other product candidates in various stages of development, including ITOS-6820, a small molecule inhibitor of the lysine-specific demethylase 1 (LSD1) enzyme, which is being developed for the treatment of small cell lung cancer, and ITOS-1480, an inhibitor of the immunosuppressive enzyme arginase 1, which is being developed for the treatment of solid tumors.
The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.
|
